Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0001193125-25-286212

Chief Scientific Officer sold 8,500 shares at an average $25.19 ($214,091)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Bredt David Chief Scientific Officer 2025-11-17 Sale 10b5-1 −3,156 $24.84 $78,395 406,486 D: show line 1 in the form
Bredt David Chief Scientific Officer 2025-11-17 Sale 10b5-1 −5,344 $25.39 $135,696 401,142 D: show line 2 in the form
Open-market sales · 8,500 sh · avg $25.19 · $214,091
Loading xslF345X05/ownership.xml…